Integrinβ6-targeted immunoliposomes mediate tumor-specific drug delivery and enhance therapeutic efficacy in colon carcinoma

Clinical Cancer Research

Volumn 21, Issue 5, 2015, Pages 1183-1195

  Liang, Benjia ^a,b   Shahbaz, Muhammad ^a   Wang, Yang ^c   Gao, Huijie ^a,b   Fang, Ruliang ^a   Niu, Zhengchuan ^a,b   Liu, Song ^a,b   Wang, Ben ^a,b   Sun, Qi ^a,b   Niu, Weibo ^a   Liu, Enyu ^a   Wang, Jiayong ^a   Niu, Jun ^a  

^a SHANDONG UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA6 INTEGRIN; CASPASE 3; CYTOCHROME C; FLUOROURACIL; IMMUNOLIPOSOME; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; BETA INTEGRIN; LIPOSOME; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; CANCER CELL; CELL SURFACE; COLON CANCER; COLON CARCINOMA; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG TISSUE LEVEL; FEMALE; HT 29 CELL LINE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR REGRESSION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA; CELL PROLIFERATION; COLONIC NEOPLASMS; DISEASE MODEL; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; PARTICLE SIZE; PATHOLOGY; TISSUE DISTRIBUTION; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; FEMALE; FLUOROURACIL; GENE EXPRESSION; HUMANS; INTEGRIN BETA CHAINS; LIPOSOMES; MICE; MOLECULAR TARGETED THERAPY; PARTICLE SIZE; TISSUE DISTRIBUTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84928810241     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1194     Document Type: Article

References (48)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Gill S, Loprinzi CL, Sargent DJ, Thome SD, Alberts SR, Haller DG, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004;22:1797-806.
3. Van Cutsem E, Costa F. Progress in the adjuvant treatment of colon cancer: has it influenced clinical practice? JAMA 2005;294:2758-60.
4. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A 1991; 88:11460-4.
5. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005;4:145-60.
6. Horowitz AT, Barenholz Y, Gabizon AA. In vitro cytotoxicity of liposomeencapsulated doxorubicin: dependence on liposome composition and drug release. Biochim Biophys Acta 1992;1109:203-9.
7. Noble CO, Kirpotin DB, Hayes ME, Mamot C, Hong K, Park JW, et al. Development of ligand-targeted liposomes for cancer therapy. Expert Opin Ther Targets 2004;8:335-53.
8. Lukyanov AN, Elbayoumi TA, Chakilam AR, Torchilin VP. Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody. J Control Release 2004;100:135-44.
9. Park JW, Benz CC, Martin FJ. Future directions of liposome-and immunoliposome-based cancer therapeutics. Semin Oncol 2004;31: 196-205.
10. Molavi O, Xiong XB, Douglas D, Kneteman N, Nagata S, Pastan I, et al. Anti-CD30 antibody conjugated liposomal doxorubicin with significantly improved therapeutic efficacy against anaplastic large cell lymphoma. Biomaterials 2013;34:8718-25.
11. Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 2002;8:1172-81.
12. Mamot C, Drummond DC, Greiser U, Hong K, Kirpotin DB, Marks JD, et al. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFRand EGFRvIII-overexpressing tumor cells. Cancer Res 2003;63: 3154-61.
13. Wicki A, Rochlitz C, Orleth A, Ritschard R, Albrecht I, Herrmann R, et al. Targeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth. Clin Cancer Res 2012;18:454-64.
14. Mamot C, Ritschard R, Wicki A, Stehle G, Dieterle T, Bubendorf L, et al. Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 doseescalation study. Lancet Oncol 2012;13:1234-41.
15. Weinacker A, Chen A, Agrez M, Cone RI,Nishimura S,Wayner E, et al. Role of the integrin alpha v beta 6 in cell attachment to fibronectin. Heterologous expression of intact and secreted forms of the receptor. J Biol Chem 1994;269:6940-8.
16. Breuss JM, Gallo J, DeLisser HM, Klimanskaya IV, Folkesson HG, Pittet JF, et al. Expression of the beta 6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling. J Cell Sci 1995;108:2241-51.
17. Yang GY, Xu KS, Pan ZQ, Zhang ZY, Mi YT, Wang JS, et al. Integrin alpha v beta 6 mediates the potential for colon cancer cells to colonize in and metastasize to the liver. Cancer Sci 2008;99:879-87.
18. Bates RC, Bellovin DI, Brown C, Maynard E, Wu B, Kawakatsu H, et al. Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J Clin Invest 2005;115:339-47.
19. Liu S, Wang J, Niu W, Liu E, Wang J, Peng C, et al. The beta6-integrin-ERK/MAP kinase pathway contributes to chemo resistance in colon cancer. Cancer Lett 2013;328:325-34.
20. Kimura RH, Teed R, Hackel BJ, Pysz MA, Chuang CZ, Sathirachinda A, et al. Pharmacokinetically stabilized cystine knot peptides that bind alpha-v-beta-6 integrin with single-digit nanomolar affinities for detection of pancreatic cancer. Clin Cancer Res 2012;18: 839-49.
21. Ueda M, Fukushima T, Ogawa K, Kimura H, Ono M, Yamaguchi T, et al. Synthesis and evaluation of a radioiodinated peptide probe targeting alphavbeta6 integrin for the detection of pancreatic ductal adenocarcinoma. Biochem Biophys Res Commun 2014;445:661-6.
22. Zhao-Yang Z, Ke-Sen X, Qing-Si H, Wei-Bo N, Jia-Yong W, Yue-Tang M, et al. Signaling and regulatory mechanisms of integrin alphavbeta6 on the apoptosis of colon cancer cells. Cancer Lett 2008;266:209-15.
23. Kogelberg H, Tolner B, Thomas GJ, Di Cara D, Minogue S, Ramesh B, et al. Engineering a single-chain Fv antibody to alpha v beta 6 integrin using the specificity-determining loop of a foot-and-mouth disease virus. J Mol Biol 2008;382:385-401.
24. Ahmed N, Niu J, Dorahy DJ, Gu X, Andrews S, Meldrum CJ, et al. Direct integrin alphavbeta6-ERK binding: implications for tumour growth. Oncogene 2002;21:1370-80.
25. Wang J, Zhang Z, Xu K, Sun X, Yang G,Niu W, et al. Suppression of integrin alphaupsilonbeta6 by RNA interference in colon cancer cells inhibits extracellular matrix degradation through the MAPK pathway. Int J Cancer 2008;123:1311-7.
26. Liu D, Liu F, Liu Z, Wang L, Zhang N. Tumor specific delivery and therapy by double-targeted nanostructured lipid carriers with anti-VEGFR-2 antibody. Mol Pharm 2011;8:2291-301.
27. Wei M, Xu Y, Zou Q, Tu L, Tang C, Xu T, et al. Hepatocellular carcinoma targeting effect of PEGylated liposomes modified with lactoferrin. Eur J Pharm Sci 2012;46:131-41.
28. Luo LM, Huang Y, Zhao BX, Zhao X, Duan Y, Du R, et al. Anti-tumor and anti-angiogenic effect of metronomic cyclic NGR-modified liposomes containing paclitaxel. Biomaterials 2013;34:1102-14.
29. Alvi IA, Madan J, Kaushik D, Sardana S, Pandey RS, Ali A. Comparative study of transfersomes, liposomes, and niosomes for topical delivery of 5-fluorouracil to skin cancer cells: preparation, characterization, in-vitro release, and cytotoxicity analysis. Anticancer Drugs 2011;22:774-82.
30. Gupta Y, Jain A, Jain P, Jain SK. Design and development of folate appended liposomes for enhanced delivery of 5-FU to tumor cells. J Drug Target 2007;15:231-40.
31. Li J, Hou N, Faried A, Tsutsumi S, Takeuchi T, Kuwano H. Inhibition of autophagy by 3-MA enhances the effect of 5-FU-induced apoptosis in colon cancer cells. Ann Surg Oncol 2009;16:761-71.
32. Casale F, Canaparo R, Serpe L, Muntoni E, Pepa CD, Costa M, et al. Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients. Pharmacol Res 2004;50:173-9.
33. Wu J, Lu Y, Lee A, Pan X, Yang X, Zhao X, et al. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil. J Pharm Sci 2007;10:350-7.
34. Massing U, Fuxius S. Liposomal formulations of anticancer drugs: selectivity and effectiveness. Drug Resist Updat 2000;3:171-7.
35. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001;41:189-207.
36. Bae YH, Park K. Targeted drug delivery to tumors: myths, reality and possibility. J Control Release 2011;153:198-205.
37. Gao J, Chen H, Song H, Su X, Niu F, Li W, et al. Antibody-targeted immunoliposomes for cancer treatment. Mini Rev Med Chem 2013;13: 2026-35.
38. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev 2013;65:36-48.
39. Wang J, Wu J, Hong J, Chen R, Xu K, Niu W, et al. PKC promotes the migration of colon cancer cells by regulating the internalization and recycling of integrin alphavbeta6. Cancer Lett 2011;311:38-47.
40. Zhao YZ, Dai DD, Lu CT, Chen LJ, Lin M, Shen XT, et al. Epirubicin loaded with propylene glycol liposomes significantly overcomes multidrug resistance in breast cancer. Cancer Lett 2013;330:74-83.
41. Gabizon AA. Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet. Clin Cancer Res 2001;7:223-5.
42. Yang X, Zheng F, Xing H, Gao Q, Wei W, Lu Y, et al. Resistance to chemotherapy-induced apoptosis via decreased caspase-3 activity and overexpression of antiapoptotic proteins in ovarian cancer. J Cancer Res Clin Oncol 2004;130:423-8.
43. Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 2004;23:2934-49.
44. Huang SK, Lee KD, Hong K, Friend DS, Papahadjopoulos D. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res 1992;52:5135-43.
45. Niu W, Liu X, Zhang Z, Xu K, Chen R, Liu E, et al. Effects of alphavbeta6 gene silencing by RNA interference in PANC-1 pancreatic carcinoma cells. Anticancer Res 2010;30:135-42.
46. Zhang ZY, Xu KS, Wang JS, Yang GY, Wang W, Wang JY, et al. Integrin alphanvbeta6 acts as a prognostic indicator in gastric carcinoma. Clin Oncol 2008;20:61-6.
47. Ahmed N, Pansino F, Clyde R, Murthi P, Quinn MA, Rice GE, et al. Overexpression of alpha(v)beta6 integrin in serous epithelial ovarian cancer regulates extracellular matrix degradation via the plasminogen activation cascade. Carcinogenesis 2002;23:237-44.
48. Elayadi AN, Samli KN, Prudkin L, Liu YH, Bian A, Xie XJ, et al. A peptide selected by biopanning identifies the integrin alphavbeta6 as a prognostic biomarker for nonsmall cell lung cancer. Cancer Res 2007;67:5889-95.